ngµç×ÓÓÎÏ·ÐÂÎÅÍøѶ£¨Í¨Ñ¶Ô±ÕÅæÃæᢡ¢¡¢´÷Ï£°²¡¢¡¢¡¢¼òÎÄÑ¹ØÓÚ¾Ö²¿ÍíÆÚµÄÖ±³¦°©£¬£¬ÏÖÔÚÖ÷Òª½ÓÄÉи¨ÖúÖÎÁƽµµÍÖ×Áö·ÖÆÚÒÔ¸ÄÉÆÖÎÁÆЧ¹û£¬£¬¿ÉÊÇÓÐÏ൱һ²¿·ÖµÄ»¼Õ߶Ôи¨Öú»¯ÁÆÄÍÒ©£¬£¬Ô¤ºó¼«²î¡£Òò´Ë£¬£¬ÉîÈë̽Ë÷Ö±³¦°©¶Ôи¨Öú»¯ÁÆÄÍÒ©µÄ·Ö×Ó»úÖÆ£¬£¬ÓÐÀûÓÚ·¢Ã÷еÄÖÎÁưе㣬£¬¿ª·¢ÐµÄÖÎÁÆ·½°¸¡£¿ËÈÕ£¬£¬Á¥ÊôµÚÁùÒ½ÔºÎâС½£¡¢¡¢¡¢ÓàÕÕÁÁ¿ÎÌâ×éÓëÁ¥ÊôÖ×ÁöҽԺ̷¾²¿ÎÌâ×éÔÚÃÀ¹ú¹ú¼Ò¿ÆѧԺԺ¿¯PNASÉϽÒÏþÁËÌâΪPharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancerµÄÑо¿ÂÛÎÄ¡£Ñо¿ÍŶÓͨ¹ýÃè»æи¨Öú»¯ÁÆÄÍÒ©ÐÍÖ±³¦°©µÄÖ×Áö·Ö×ÓÌØÕ÷, Á¬Ïµ¸ßͨÁ¿Ò©É¸É¸Ñ¡£¬£¬·¢Ã÷CDK4/6ÒÖÖƼÁ¿ÉÒÔÓÐÓÃÌá¸ß°ÂɳÀû²¬ÁÆЧ£¬£¬½øÒ»²½Ê¹Óöà×éѧ²âÐòÊÖÒÕ£¨È«×ªÂ¼×é²âÐòºÍ±í¹ÛÒÅ´«×é²âÐòµÈ£©Õ¹ÏÖÁ˵±ÖеķÖ×Ó»úÖÆ£¬£¬ÎªÐ¸¨Öú»¯ÁÆÄÍÒ©µÄÖ±³¦°©»¼ÕßÌṩÁËеÄÖÎÁÆ˼Ð÷¡£
и¨Öú»¯ÁÆÊÇÏÖÔÚÁÙ´²ÉÏÖÎÁƾֲ¿ÍíÆÚÖ±³¦°©µÄÖ÷ÒªÊֶΣ¬£¬¿ÉÊÇÔ¼30%-60%µÄÖ±³¦°©»¼Õ߶ÔÏÖÔÚи¨Öú»¯ÁÆ·½°¸²»Ãô¸Ð£¬£¬Ö×ÁöÍËËõ½ÏС»òÕßÉõÖÁ²»ÍËËõ£¬£¬È»¶øÁÙ´²ÉÏÓÖȱ·¦¸ü¶àµÄÒ©ÎïÖÎÁÆÑ¡Ôñ£¬£¬ÕâȺ»¼ÕßµÄÊõºó¸¨ÖúÖÎÁƶàÊǼÌÐøÑØÓÃÒ»ÏߵĻ¯ÁÆ·½°¸£¬£¬Ô¤ºó¼«²î¡£ÎªÁË̽Ë÷³¦°©Ð¸¨Öú»¯ÁÆÄÍÒ©µÄÖ×Áö·Ö×ÓÌØÕ÷£¬£¬Ñо¿ÍŶÓÊ×ÏÈÍøÂçÁËÈ´Ö±³¦°©Ö×Áö×éÖ¯¾ÙÐÐת¼×é²âÐò£¬£¬ÔÙ¸ú×ÙËæ·Ã²¡ÈË»¯ÁÆЧ¹û£¬£¬Æ¾Ö¤ÁÆЧ°Ñ²¡ÈË·ÖΪ»¯ÁÆÃô¸ÐÐͺÍÄÍÒ©ÐÍ£¬£¬¾ÙÐзÖ×éÆÊÎö¡£Ð§¹û·¢Ã÷ÄÍÒ©ÐÍÖ×Áö×éÖ¯ÖÐϸ°ûÖÜÆÚÏà¹ØµÄÐźÅÒì³£»£»î»¯£¬£¬ÌáÐÑÒÔ¡°°ÐÏòÒì³£µÄϸ°ûÖÜÆÚ¼ì²éµã¡±Ñ°ÕÒÖÎÁưеã¿ÉÄÜ¿ÉÒÔÄæת»¯ÁÆÄÍÒ©¡£ÓÚÊǽøÒ»²½Ê¹ÓÃС·Ö×ÓÒÖÖƼÁÎÄ¿â¾ÙÐиßͨÁ¿É¸Ñ¡£¬£¬·¢Ã÷CDK4/6ÒÖÖƼÁ¿ÉÒÔÓÐÓÃÌá¸ß°ÂɳÀû²¬Ãô¸ÐÐÔ£¬£¬²¢ÇÒ¿ÉÒÔÐͬÒÖÖÆÖ×Áöϸ°ûÔöÖ³¡£»£»úÖÆÉÏ£¬£¬Í¨¹ýÕûºÏȫת¼×é²âÐòÆÊÎöºÍȾɫÖʹ²³Áµí²âÐòÆÊÎö·¢Ã÷CDK4/6ÒÖÖƼÁͨ¹ýÓ°Ïì±í¹ÛÒÅ´«ÐÞÊε÷¿ØͬԴÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï£¬£¬´Ó¶øÚ¹ÊÍÁËCDK4/6ÒÖÖƼÁΪºÎ¿ÉÒÔÄæת°ÂɳÀû²¬ÄÍÒ©Õ÷ÏóµÄ»úÖÆ£¬£¬¸ÃÑо¿ÓÐÍûΪи¨Öú»¯ÁÆÄÍÒ©µÄÖ±³¦°©»¼ÕßÌṩеÄÓÃÒ©Ñ¡Ôñ£¨Í¼1£©¡£
ͼ1 CDK4/6ÒÖÖƼÁͨ¹ýÓ°Ïì±í¹ÛÒÅ´«ÐÞÊε÷¿ØͬԴÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï£¬£¬´Ó¶øÄæת°ÂɳÀû²¬ÄÍÒ©Õ÷Ïó
Ñо¿ÍŶÓͨ¹ýÍøÂç34Àýи¨ÖúÖÎÁÆÇ°µÄ¾Ö²¿Ï£ÍûÆÚÖ±³¦°©»¼ÕßÖ×ÁöÑù±¾£¬£¬Æ¾Ö¤Ð¸¨ÖúÖÎÁƺóÊÖÊõÇгýµÄÖ×ÁöÑù±¾²¡ÀíÇÐƬ¾ÙÐÐÖ×ÁöÍËËõÆÀ¼Û£¨Tumor regression grade£¬£¬TRG£©£¬£¬¶Ô²¡È˾ÙÐзÖÀ࣬£¬²¢ÆÊÎöÄÍÒ©Ïà¹ØµÄÖ×Áö·Ö×ÓÌØÕ÷£¨Í¼2£©¡£
ͼ2 и¨Öú»¯ÁÆÄÍÒ©Ïà¹ØµÄÖ×Áö·Ö×ÓÌØÕ÷
ΪÁËÑ°ÕÒÖÎÁưе㣬£¬Ñо¿ÍŶÓʹÓÃС·Ö×ÓÒÖÖƼÁÎÄ¿â¾ÙÐиßͨÁ¿Ò©Îïɸѡ£¬£¬·¢Ã÷CDK4/6ÒÖÖƼÁ¿ÉÒÔÏÔÖøÌá¸ß°ÂɳÀû²¬Ò©Ð§£¨Í¼3£©¡£
ͼ3 С·Ö×ÓÒÖÖƼÁÎÄ¿âÒ©Îïɸѡ·¢Ã÷CDK4/6ÒÖÖƼÁ¿ÉÏÔÖøÌá¸ß°ÂɳÀû²¬Ò©Ð§
×îºó£¬£¬Í¨¹ýÕûºÏÆÊÎöRNA-seqºÍChIP-seqÊý¾Ý£¬£¬CDK4/6ÒÖÖƼÁͨ¹ý±í¹ÛÒÅ´«ÐÞÊε÷¿ØRB1-TEAD4ÐźÅÖáÓ°ÏìͬԴÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï£¬£¬´Ó¶øÄæת°ÂɳÀû²¬ÄÍÒ©Õ÷Ïó£¨Í¼4£©¡£
ͼ4 CDK4/6ÒÖÖƼÁͨ¹ý±í¹ÛÒÅ´«ÐÞÊε÷¿ØͬԴÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï
ÖµµÃÒ»ÌáµÄÊÇ£¬£¬»ùÓڸûù´¡Ñо¿Ð§¹û£¬£¬ÒѽøÒ»²½¿ªÕ¹ÁÙ´²ÊÔÑ飨CDK4/6ÒÖÖƼÁÁªºÏ»¯ÁÆÓÃÓÚÍíÆÚ/תÒÆÐÔ½áÖ±³¦°©µÄÁÙ´²×ª»¯Ñо¿£¬£¬Clinical Trial£º£ºNCT05480280£©£¬£¬ÏÖÔÚ¶àÀý¾±ê×¼ÖÎÁÆʧ°ÜµÄÍíÆÚ³¦°©²¡ÈËÒÑÈë×飬£¬²¢ÒÑÊӲ쵽²¿·ÖÈë×黼ÕßÁÙ´²»ñÒ棬£¬ÆäÓÐÍûÌá¸ßи¨Öú»¯ÁÆÄÍÒ©µÄ²¡ÈËÔ¶ÆÚÁÆЧ¡£
Á¥ÊôµÚÁùÒ½ÔºÎâС½£½ÌÊÚºÍÁ¥ÊôÖ×ÁöҽԺ̷¾²Ñо¿Ô±Îª±¾ÂÛÎĵÄͨѶ×÷Õߣ¬£¬ÓàÕÕÁÁҽʦ¡¢¡¢¡¢µËÅô²©Ê¿ÒÔ¼°³Âîڷ渱Ö÷ÈÎҽʦΪ±¾ÎĵÄÅäºÏµÚÒ»×÷Õߣ¬£¬±¾Ñо¿»¹»ñµÃÁËмÓÆ»ùÒò×éÑо¿ÔºÓÚÇ¿½ÌÊÚ¡¢¡¢¡¢Ð¼ÓƹúÁ¢°©Ö¢ÖÐÐÄBin Tean Teh½ÌÊÚºÍÁ¥ÊôµÚÁùÒ½ÔºÍõÎÄÓÑо¿Ô±µÄ´óÁ¦Ö§³Ö¡£
ÂÛÎÄÁ´½Ó£º£ºhttps://doi.org/10.1073/pnas.2304619121
µØµã:¹ãÖÝÊÐиÛÎ÷·135ºÅ Óʱà:510275
µç»°: 020-84112828
ngµç×ÓÓÎÏ·°æȨËùÓÐ COPYRIGHT?1999-2022 , SUN YAT-SEN UNIVERSITY